Literature DB >> 6782183

Immunological characterization of plasminogen activator activities in human tissues and body fluids.

D C Rijken, G Wijngaards, J Welbergen.   

Abstract

Human plasminogen activators were compared immunologically in both a double-diffusion technique and quenching experiments on the fibrinolytic activities of the activators. Antisera against HMW and LMW urokinase and an antiserum against highly purified tissue plasminogen activator from human uterus were used. It was found that uterine tissue plasminogen activator and urokinase are two immunologically distinct plasminogen activators. The occurrence of the two kinds of plasminogen activators in human tissues and body fluids was studied on the basis of the quenching of the activities by antibodies. In tissue extracts, mainly tissue plasminogen activator was found. Seminal plasma exhibited a high plasminogen activator activity, consisting of both urokinase and tissue plasminogen activator-related activators. Urine contained a small amount of tissue plasminogen activator-related activator in addition to urokinase. The low plasminogen activator activities of saliva and tears were completely attributed to activators related to tissue plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6782183

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  19 in total

1.  PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Authors:  Khalid Bajou; Stephanie Herkenne; Victor L Thijssen; Salvino D'Amico; Ngoc-Quynh-Nhu Nguyen; Ann Bouché; Sébastien Tabruyn; Mohammed Srahna; Jean-Yves Carabin; Olivier Nivelles; Cécile Paques; Ivo Cornelissen; Michelle Lion; Agnès Noel; Ann Gils; Stefan Vinckier; Paul J Declerck; Arjan W Griffioen; Mieke Dewerchin; Joseph A Martial; Peter Carmeliet; Ingrid Struman
Journal:  Nat Med       Date:  2014-06-15       Impact factor: 53.440

2.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

3.  Localization of tissue plasminogen activator in the endothelium of a limited number of vessels.

Authors:  E G Levin; G J del Zoppo
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

4.  Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.

Authors:  S Thorsen; S Müllertz; E Suenson; P Kok
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

Review 5.  Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Authors:  J S Sundsmo; D S Fair
Journal:  Springer Semin Immunopathol       Date:  1983

6.  Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

Authors:  L A Erickson; M H Ginsberg; D J Loskutoff
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.

Authors:  S K Sundar; J Bergeron; J Menezes
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

8.  Insulin and insulin-like growth factor I exert different effects on plasminogen activator production or cell growth in the ovine thyroid cell line OVNIS.

Authors:  B Degryse; F Maisonobe; S Hovsépian; G Fayet
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

Authors:  E G Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.

Authors:  E G Levin; U Marzec; J Anderson; L A Harker
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.